Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

First Plant-Based Seasonal Flu Vaccine Candidate Reaches Final Clinical Stage

by Global Biodefense Staff
September 26, 2017
VLP Flu Vaccines

Medicago, a Canadian biopharmaceutical company and leader in the development and production of plant-based vaccines and therapeutics, today announced the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate.

The trial is currently taking place with 10,000 subjects in seven countries (Canada, US, UK, Germany, Finland, Thailand, and the Philippines). This efficacy study is in support of Medicago’s flu program and expected launch of the vaccine in time for the 2020 influenza season in Canada, USA and Europe.

The QIV candidate is produced using a novel virus-like particle (VLP) technology, an alternative to egg-based and cell-based production systems. VLPs mimic the native structure of viruses, allowing them to be easily recognized by the immune system. However, they lack the core genetic material, rendering them non-infectious and unable to replicate.

It currently takes only 5-6 weeks for the company to produce a clinical-grade vaccine, compared to 5-6 months using egg-based production methods.

Source: Medicago press release.

Tags: InfluenzaVaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy